Pharmaceuticals

Psoriasis Biosimilars Industry Forecast to Hit $12.43 Billion by 2029 With a Strong 11.1% CAGR

November 20, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Psoriasis Biosimilars Market Size During 2025–2029?

The psoriasis biosimilars market size has experienced rapid growth in recent years. It is projected to expand from $7.32 billion in 2024 to $8.16 billion in 2025, with a compound annual growth rate (CAGR) of 11.5%. The expansion witnessed historically can be linked to the increasing financial burden of original biologics, the clinical achievements and safety records of early market entrants, the extension of their approved uses beyond psoriasis, the rising prevalence of chronic diseases, and modifications in hospital procurement policies.

The psoriasis biosimilars market size is projected to experience substantial growth in the coming years. It is anticipated to expand to $12.43 billion by 2029, achieving a compound annual growth rate (CAGR) of 11.1%. This growth over the forecasted period stems from factors such as a global rise in psoriasis incidence, the implementation of switching policies and interchangeability laws, the expansion of biosimilar manufacturing, enhanced patient and physician education, and the adoption of bundled pricing along with value-based contracts. Key trends for this period involve innovative biosimilar manufacturing platforms, AI-driven patient stratification, the launch of advanced drug delivery devices, the creation of next-generation formulations, and strategic collaborations across the industry.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27399&type=smp

What Are The Drivers Pushing New Developments In The Psoriasis Biosimilars Market?

Increased diagnosis rates for psoriatic arthritis are anticipated to drive the expansion of the psoriasis biosimilars market in the future. Psoriatic arthritis is defined as a long-term autoimmune disorder characterized by inflammation of the joints and skin, frequently observed in those who have previously experienced psoriasis. Diagnosis rates for psoriatic arthritis are on an upward trend, primarily because of enhanced screening methods for individuals with psoriasis. These improvements facilitate earlier and more precise diagnosis by pinpointing subtle joint indicators that might have previously been overlooked. Psoriasis biosimilars contribute to managing psoriatic arthritis by offering cost-effective alternatives to biologic treatments, thereby efficiently alleviating joint inflammation and skin manifestations. To illustrate, data from May 2024, provided by the National Institutes of Health (NIH), a US-based government agency, indicated that in 2022, psoriatic arthritis (PsA) recorded a prevalence of 0.221% and an incidence rate of 13.54 per 100,000 people. Consequently, the increasing diagnosis rates of psoriatic arthritis are fueling the expansion of the psoriasis biosimilars market.

Which Key Segments Fueling The Psoriasis Biosimilars Market?

The psoriasis biosimilars market covered in this report is segmented

1) By Drug Class: TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars

2) By Disease Type: Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis

3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By TNF-Alpha Inhibitors: Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars

2) By Infliximab: Remicade Biosimilars, CT-P13 Biosimilars

3) By Etanercept: Enbrel Biosimilars, SB4 Biosimilars

4) By Adalimumab: Humira Biosimilars, ABP 501 Biosimilars

5) By Other Biosimilars: Ustekinumab Biosimilars, Secukinumab Biosimilars

What Key Innovation Trends Are Fueling Advancements In The Psoriasis Biosimilars Market?

Major companies in the psoriasis biosimilars market are concentrating on introducing novel solutions, such as biosimilars targeting plaque psoriasis, to boost access to treatment, lower healthcare expenditures, and enhance patient results. These biosimilars for plaque psoriasis offer more affordable, highly comparable alternatives to existing biologic medications used to manage the chronic autoimmune skin condition marked by red, scaly patches. For instance, in May 2025, the Switzerland-based company Sandoz Group AG, specializing in generic pharmaceuticals and biosimilars, unveiled the Pyzchiva autoinjector. This product represents the first commercially available ustekinumab biosimilar autoinjector. Pyzchiva is approved for adult patients suffering from plaque psoriasis, psoriatic arthritis, and Crohn’s disease, as well as pediatric patients aged six years and older (weighing over 60 kg) with plaque psoriasis. The autoinjector is engineered to improve patient adherence and quality of life, featuring precise automatic dosing, minimized injection discomfort, a small form factor, and adaptable storage choices for easier self-administration.

Which Major Industry Participants Are Leading The Psoriasis Biosimilars Market Growth?

Major companies operating in the psoriasis biosimilars market are Pfizer Inc., Merck & Co. Inc., Amgen Inc., Biogen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Samsung Bioepis Co. Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Torrent Pharmaceuticals Ltd., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Reliance Life Sciences Pvt. Ltd., and Alvotech hf.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/psoriasis-biosimilars-global-market-report

What Are The Key Regional Factors Influencing The Psoriasis Biosimilars Market Growth?

North America was the largest region in the psoriasis biosimilars market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psoriasis biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Psoriasis Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27399&type=smp

Browse Through More Reports Similar to the Global Psoriasis Biosimilars Market 2025, By The Business Research Company

Connected Rail Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/connected-rail-global-market-report

Rail Road Construction Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rail-road-construction-global-market-report

Freight Railcar Parts Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/freight-railcar-parts-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795